Loading stock data…
SENS
$7.43+0.30 (+4.21%)
After Hours$7.39-0.04 (-0.54%)· Last close Jun 9
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Senseonics Holdings, Inc. in the Healthcare sector is trading at $7.43. Wall Street consensus targets $13.80 (5 analysts), implying a +85.7% move over the next 12 months. The stock is currently 41% below its 52-week high of $12.58, remaining 4.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +85.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$7.43
Potential Downside
0%
Whystock Fair Value$7.43
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$13.80+85.7%
Range$8.00 – $20.00
Fundamentals
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-253.93%
Volume
Today's trading volume
777,641
Recent News
Senseonics Holdings, Inc. Common Stock Q1 Earnings Call Highlights
Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) raised its full-year 2026 revenue outlook after reporting first-quarter growth tied to adoption of its Eversense 365 continuous glucose monitoring system and the integration of its U.S. commercial organization. President and CEO Tim Goodnow said
Senseonics Holdings (SENS) Reports Q1 Loss, Beats Revenue Estimates
Senseonics (SENS) delivered earnings and revenue surprises of -9.23% and +16.81%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Top Midday Decliners
BayFirst Financial's (BAFN) shares sank 28% after the company reported a wider Q1 loss and lower rev
Study Supports GlucoTrack’s Blood Glucose Monitoring Implant
By Karen Roman GlucoTrack, Inc. (Nasdaq: GCTK) said a peer-reviewed study published in the Institute of Electrical and Electronics Engineers Sensors Journal supported the feasibility of long-life implantable continuous glucose monitors like the devices the company develops. The article came out on April 7, 2026, and is the result of a partnership between GlucoTrack and […]
3 European Stocks Estimated To Be Trading At Discounts Of Up To 48.2%
As European markets rally following a U.S.-Iran ceasefire, the STOXX Europe 600 Index has seen a significant gain of 3.05%, with major indices in Germany, Italy, and France also posting strong performances. Amid this optimistic environment, identifying undervalued stocks can be particularly appealing as investors look for opportunities that may benefit from improved sentiment and potential market recovery.